PL1809320T3 - Kompozycje zawierające lipazę, proteazę i amylazę do leczenia niewydolności trzustki - Google Patents

Kompozycje zawierające lipazę, proteazę i amylazę do leczenia niewydolności trzustki

Info

Publication number
PL1809320T3
PL1809320T3 PL05814918T PL05814918T PL1809320T3 PL 1809320 T3 PL1809320 T3 PL 1809320T3 PL 05814918 T PL05814918 T PL 05814918T PL 05814918 T PL05814918 T PL 05814918T PL 1809320 T3 PL1809320 T3 PL 1809320T3
Authority
PL
Poland
Prior art keywords
pancreatic insufficiency
amylase
protease
compositions containing
treating pancreatic
Prior art date
Application number
PL05814918T
Other languages
English (en)
Inventor
Alexey L Margolin
Bhami C Shenoy
Frederick T Murray
Anthony Christopher Lee Stevens
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PL1809320T3 publication Critical patent/PL1809320T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/465Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL05814918T 2004-10-14 2005-10-14 Kompozycje zawierające lipazę, proteazę i amylazę do leczenia niewydolności trzustki PL1809320T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61876404P 2004-10-14 2004-10-14
EP05814918A EP1809320B1 (en) 2004-10-14 2005-10-14 Compositions containing lipase; protease and amylase for treating pancreatic insufficiency
PCT/US2005/036802 WO2006044529A1 (en) 2004-10-14 2005-10-14 Compositions containing lipase; protease and amylase for treating pancreatic insufficiency

Publications (1)

Publication Number Publication Date
PL1809320T3 true PL1809320T3 (pl) 2011-11-30

Family

ID=35840531

Family Applications (2)

Application Number Title Priority Date Filing Date
PL10158639T PL2198880T3 (pl) 2004-10-14 2005-10-14 Kompozycje zawierające lipazę, proteazę i amylazę do leczenia niewydolności trzustki
PL05814918T PL1809320T3 (pl) 2004-10-14 2005-10-14 Kompozycje zawierające lipazę, proteazę i amylazę do leczenia niewydolności trzustki

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL10158639T PL2198880T3 (pl) 2004-10-14 2005-10-14 Kompozycje zawierające lipazę, proteazę i amylazę do leczenia niewydolności trzustki

Country Status (23)

Country Link
US (1) US7718169B2 (pl)
EP (2) EP2198880B1 (pl)
JP (1) JP4908420B2 (pl)
KR (1) KR101333664B1 (pl)
CN (1) CN101068565B (pl)
AT (1) ATE474592T1 (pl)
AU (1) AU2005295754B2 (pl)
BR (1) BRPI0516515B1 (pl)
CA (1) CA2584069C (pl)
CY (2) CY1110838T1 (pl)
DE (1) DE602005022471D1 (pl)
DK (2) DK2198880T3 (pl)
ES (2) ES2614157T3 (pl)
HR (1) HRP20161684T1 (pl)
HU (1) HUE031245T2 (pl)
LT (1) LT2198880T (pl)
MX (1) MX2007004534A (pl)
PL (2) PL2198880T3 (pl)
PT (2) PT1809320E (pl)
RU (1) RU2385736C2 (pl)
SI (2) SI1809320T1 (pl)
UA (1) UA91521C2 (pl)
WO (1) WO2006044529A1 (pl)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US20010046493A1 (en) * 2000-02-24 2001-11-29 Alex Margolin Lipase-containing composition and methods of use thereof
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
IT1319655B1 (it) 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
PT1729797E (pt) 2004-03-22 2008-12-17 Solvay Pharm Gmbh Composições farmacêuticas orais de produtos contendo lipase, em particular de pancreatina, contendo tensioactivos
EP1771194A2 (en) * 2004-07-07 2007-04-11 Biodevelops Pharma Entwicklung GmbH Use of a deubiquitinating compound for enhancing the expression of membrane proteins on the cell surface
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
EP1913138B1 (en) 2005-07-29 2016-08-24 Abbott Laboratories GmbH Processes for the manufacture of pancreatin powder with low virus content
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US20070116695A1 (en) * 2005-09-21 2007-05-24 Fallon Joan M Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders
US8071089B2 (en) * 2005-11-01 2011-12-06 Bio-Cat, Inc. Composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrosis as well as people suffering from pancreatic lipase insufficiency
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
WO2008079685A2 (en) 2006-12-21 2008-07-03 Novozymes A/S Lipase variants for pharmaceutical use
US20080199448A1 (en) * 2007-02-16 2008-08-21 Ross Mairi R Enzyme composition for improving food digestion
RU2445952C2 (ru) * 2007-02-20 2012-03-27 Юранд Фармасьютикалз Лимитед Стабильные композиции пищеварительных ферментов
WO2008102264A2 (en) 2007-02-20 2008-08-28 Eurand Pharmaceuticals Limited Stable digestive enzyme compositions
US10087493B2 (en) 2008-03-07 2018-10-02 Aptalis Pharma Canada Ulc Method for detecting infectious parvovirus in pharmaceutical preparations
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US20090324730A1 (en) * 2008-06-26 2009-12-31 Fallon Joan M Methods and compositions for the treatment of symptoms of complex regional pain syndrome
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
PL2318035T3 (pl) 2008-07-01 2019-10-31 Curemark Llc Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
US10776453B2 (en) * 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
WO2010025126A1 (en) * 2008-08-26 2010-03-04 Cystic Fibrosis Foundation Therapeutics, Inc. Rapidly disintegrating tablets comprising lipase, amylase, and protease
EP2165717A1 (de) 2008-08-27 2010-03-24 Nordmark Arzneimittel GmbH & Co.KG Verfahren zur Verringerung der viralen und mikrobiellen Belastung feststoffhaltiger biologischer Extrakte
US20110171294A1 (en) * 2008-09-30 2011-07-14 Dsm Ip Assets B.V. Enzyme composition and application thereof in the treatment of pancreatic insufficiency
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
KR20170005191A (ko) * 2009-01-06 2017-01-11 큐어론 엘엘씨 이. 콜라이에 의한 구강 감염의 치료 또는 예방을 위한 조성물 및 방법
DK3064217T3 (en) * 2009-01-06 2018-05-28 Galenagen Llc COMPOSITIONS COMPREHENSIVE PROTEASE, AMYLASE AND LIPASE FOR USE IN TREATMENT OF STAPHYLOCOCCUS AUREUS INFECTIONS
AU2015252099B2 (en) * 2009-01-06 2017-08-10 Galenagen, Llc Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces
PT2391382E (pt) * 2009-01-29 2014-08-22 Nordmark Arzneimittel Gmbh & Co Kg Preparado farmacêutico contendo lipase de origem bacteriana
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
WO2010130622A1 (en) * 2009-05-11 2010-11-18 Dsm Ip Assets B.V. Enzyme composition for the treatment of prancreatic insufficiency
PL2295039T5 (pl) 2009-08-28 2023-02-27 Nordmark Pharma Gmbh Sposób wytwarzania granulek zawierających pankreatynę, w szczególności mikrogranulek zawierających pankreatynę, oraz wytworzone tym sposobem granulki zawierające pankreatynę
US8784884B2 (en) * 2009-09-17 2014-07-22 Stephen Perrett Pancreatic enzyme compositions and methods for treating pancreatitis and pancreatic insufficiency
AU2016216662B2 (en) * 2009-09-17 2017-09-07 Allergan Therapeutics LLC Pancreatic enzyme compositions and methods for treating pancreatitis and pancreatic insufficiency
WO2011050135A1 (en) 2009-10-21 2011-04-28 Curemark Llc Methods and compositions for the prevention and treatment of influenza
US20110135728A1 (en) * 2009-12-08 2011-06-09 Miller Jennifer L Gastric retentive pharmaceutical compositions for extended release of polypeptides
RU2429291C1 (ru) * 2009-12-28 2011-09-20 Российская Федерация, от имени которой выступает Министерство образования и науки Российской Федерации (Минобрнауки России) Пищеварительное средство на основе ферментов микробного происхождения
JP2011162491A (ja) * 2010-02-10 2011-08-25 Ezaki Glico Co Ltd 乾燥麹抽出物及びこれを用いた口腔用組成物
SE535296C2 (sv) * 2010-09-08 2012-06-19 Anara Ab Mognad av mag-tarmkanalen
KR101968457B1 (ko) 2010-10-01 2019-04-11 앨러간 파마슈티컬스 인터내셔널 리미티드 장용 코팅된 저 강도 췌장 리파제 제제
FR2966734B1 (fr) 2010-10-29 2014-07-18 Max Rombi Composition comprenant au moins une enzyme proteolytique pour son utilisation pour empecher la synthese des triglycerides
PL2489349T3 (pl) 2011-02-17 2014-09-30 Nordmark Arzneimittel Gmbh & Co Kg Granulki pankreatynowe, zwłaszcza mikrogranulki pankreatynowe, oraz sposób ich produkcji
BR112013027034A8 (pt) 2011-04-21 2018-01-02 Curemark Llc "compostos para o tratamento de transtornos neuropsiquiátricos."
MX351014B (es) 2011-08-08 2017-09-28 Aptalis Pharma Ltd Metodo para la prueba de disolucion de composiciones solidas que contienen enzimas digestivas.
US8268305B1 (en) 2011-09-23 2012-09-18 Bio-Cat, Inc. Method and compositions to reduce serum levels of triacylglycerides in human beings using a fungal lipase
EP4147690A1 (en) * 2012-02-17 2023-03-15 Alcresta Therapeutics, Inc. Methods, compositions, and devices for supplying dietary fatty acid needs
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
EP3398594B1 (en) * 2012-09-19 2024-07-10 Grespo AB Compositions for improvement of brain function
US20140276632A1 (en) 2013-03-15 2014-09-18 Aptalis Pharma Ltd. Composition containing digestive enzymes and nutrients suitable for enteral administration
US9861681B2 (en) 2013-04-18 2018-01-09 The United States of America as represented by the Secretary of the Army, on behalf of the United States Army Medical Research Institute of Infectious Diseases Therapeutic compositions for neutralizing type I interferons, and methods of use
MX2016000794A (es) 2013-07-22 2016-12-02 Allergan Pharmaceuticals Int Ltd Composiciones farmaceuticas de pancreatina de potencia alta.
JP2016537387A (ja) 2013-08-09 2016-12-01 アラガン ファーマシューティカルズ インターナショナル リミテッド 経腸投与に適した消化酵素組成物
JP2017500885A (ja) 2013-11-05 2017-01-12 アラガン ファーマシューティカルズ インターナショナル リミテッド 高力価パンクレアチン医薬組成物
JP2014193909A (ja) * 2014-06-04 2014-10-09 Nordmark Arzneimittel Gmbh & Co Kg 医薬調製物
MX2016016907A (es) 2014-06-19 2018-04-26 Aptalis Pharma Ltd Metodo para eliminar contaminantes virales de extractos pancreaticos.
GB201501081D0 (en) 2015-01-22 2015-03-11 Cilian Ag Use of enzymes with a wide pH activity range as medicaments for promoting digestion
DK3267197T3 (da) * 2015-03-02 2020-10-12 Toray Industries Fremgangsmåde og kit til detektionen af pankreatisk dysfunktion
DE102015114859A1 (de) 2015-09-04 2017-03-09 Nordmark Arzneimittel Gmbh & Co. Kg Verwendung einer pharmazeutischen Zusammensetzung, enthaltend mindestens ein Verdauungsenzym, bei der künstlichen Ernährung
US10258590B2 (en) 2015-10-14 2019-04-16 Alcresta Therapeutics, Inc. Enteral feeding device and related methods of use
DE102017104472A1 (de) 2017-03-03 2018-09-06 Nordmark Arzneimittel Gmbh & Co. Kg Schmelztablette enthaltend Burlulipase und daraus hergestellte pharmazeutische Zusammensetzung
AU2018250823A1 (en) 2017-04-10 2019-10-17 Curemark, Llc Compositions for treating addiction
US11045396B2 (en) 2017-08-17 2021-06-29 Alcresta Therapeutics, Inc. Devices and methods for the supplementation of a nutritional formula
FR3079146B1 (fr) 2018-03-23 2020-04-17 Karim Ioualalen Formulation gastroprotectrice de complexes d’enzymes permettant de restaurer la fonction digestive.
US11547745B1 (en) * 2018-08-23 2023-01-10 Vets Plus, Inc. Compositions and methods for treating pancreatic enzyme deficiencies in mammals
ES3007439T3 (en) 2019-08-30 2025-03-20 Nestle Sa Engineered lipase variants
WO2021202363A1 (en) * 2020-03-30 2021-10-07 Wall Jai Combined animal-derived and synthetically produced pancreatic enzyme replacement therapy
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
WO2023056469A2 (en) * 2021-09-30 2023-04-06 Synspira Therapeutics, Inc. Engineered lipase enzymes, manufacture and use thereof
WO2025054130A1 (en) 2023-09-05 2025-03-13 The Regents Of The University Of California Enzymes for oxidizing beta-hydroxybutyrate (bhb), test strips, and sensors of using the same

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5017559B2 (pl) 1972-09-20 1975-06-21
JPS5428820Y2 (pl) * 1974-06-14 1979-09-14
GB1509866A (en) * 1975-06-10 1978-05-04 Johnson & Johnson Enteric coated digestive enzyme compositions
US4659667A (en) * 1985-02-26 1987-04-21 Miles Laboratories, Inc. Process to recover crystalline enzymes and crystalline enzymes produced thereby
DK154572C (da) * 1985-08-07 1989-04-24 Novo Industri As Enzymatisk detergentadditiv, detergent og fremgangsmaade til vask af tekstiler
JP3079276B2 (ja) * 1988-02-28 2000-08-21 天野製薬株式会社 組換え体dna、それを含むシュードモナス属菌及びそれを用いたリパーゼの製造法
DE3808695A1 (de) * 1988-03-16 1989-10-05 Henkel Kgaa Fluessiges waschmittel
EP0387945B1 (en) 1989-03-08 1993-11-03 Simon Lodewijk Scharpé A composition for the treatment of exocrine insufficiency of the pancreas, and the use of said composition
JPH05502584A (ja) 1989-12-21 1993-05-13 ノボ ノルディスク アクティーゼルスカブ 酵素含有調製品及び該調製品を含有する洗剤
DK173590D0 (da) 1990-06-06 1990-07-19 Novo Nordisk As Rekombinante terapeutiske lipaser
US5618710A (en) * 1990-08-03 1997-04-08 Vertex Pharmaceuticals, Inc. Crosslinked enzyme crystals
HUT65904A (en) 1990-08-03 1994-07-28 Vertex Pharma Method for immobilization of enzyme in the form of crosslinked crystals
US5892013A (en) * 1990-09-13 1999-04-06 Novo Nordisk A/S Lipase variants
JP3593550B2 (ja) * 1991-07-01 2004-11-24 ノルトマルク アルツナイミッテル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディートゲゼルシャフト 医薬品製造のためのリパーゼの使用
JPH07504561A (ja) * 1991-12-20 1995-05-25 ノボ ノルディスク アクティーゼルスカブ リパーゼの製造のための方法
NZ253748A (en) * 1992-06-30 1997-06-24 Cortecs Ltd Use of enzymes especially proteolytic enzymes in the management or treatment of diarrhoea
DK154292D0 (da) * 1992-12-23 1992-12-23 Novo Nordisk As Nyt enzym
DK39693D0 (da) * 1993-04-02 1993-04-02 Novo Nordisk As Enzym
GB9403344D0 (en) * 1994-02-22 1994-04-13 Cortecs Ltd Medical application of bromelain
DE4408152A1 (de) * 1994-03-11 1995-09-14 Studiengesellschaft Kohle Mbh Immobilisierte Lipasen in hydrophoben Sol-Gel-Materialien
US6017866A (en) * 1994-05-04 2000-01-25 Genencor International, Inc. Lipases with improved surfactant resistance
AU6221496A (en) * 1995-05-31 1996-12-18 Simon Lodewijk Scharpe Composition to improve digestibility and utilisation of nutr ients
US5932212A (en) 1996-05-24 1999-08-03 Altus Biologics, Inc. Crosslinked protein crystal formulations and their use as catalysts in organic solvents
US5750104A (en) * 1996-05-29 1998-05-12 Digestive Care Inc. High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith
US6140475A (en) 1997-04-11 2000-10-31 Altus Biologics Inc. Controlled dissolution crosslinked protein crystals
AU8772498A (en) 1997-09-05 1999-03-29 Altus Biologics Inc. Carbohydrate crosslinked glycoprotein crystals
US6013680A (en) * 1997-10-21 2000-01-11 Amano Pharmaceutical Co., Ltd. Digestive enzyme-containing medicament
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
WO1999055310A1 (en) 1998-04-27 1999-11-04 Altus Biologics Inc. Stabilized protein crystals, formulations containing them and methods of making them
US6156552A (en) * 1998-02-18 2000-12-05 Novo Nordisk A/S Lipase variants
US6042823A (en) * 1998-07-02 2000-03-28 Amano Pharmaceuticals Co., Ltd. Enzyme composition and use thereof
US20010046493A1 (en) * 2000-02-24 2001-11-29 Alex Margolin Lipase-containing composition and methods of use thereof
AR032392A1 (es) * 2001-01-19 2003-11-05 Solvay Pharm Gmbh Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado.

Also Published As

Publication number Publication date
WO2006044529A1 (en) 2006-04-27
CA2584069C (en) 2017-02-07
PT1809320E (pt) 2010-10-25
US7718169B2 (en) 2010-05-18
BRPI0516515A (pt) 2008-09-16
EP2198880A1 (en) 2010-06-23
CN101068565A (zh) 2007-11-07
SI2198880T1 (sl) 2017-02-28
JP4908420B2 (ja) 2012-04-04
DK1809320T3 (da) 2010-11-15
JP2008516965A (ja) 2008-05-22
AU2005295754A2 (en) 2010-09-02
ATE474592T1 (de) 2010-08-15
BRPI0516515B1 (pt) 2018-05-29
ES2352086T3 (es) 2011-02-15
PL2198880T3 (pl) 2017-04-28
HRP20161684T1 (hr) 2017-02-24
DK2198880T3 (en) 2017-01-23
UA91521C2 (ru) 2010-08-10
PT2198880T (pt) 2017-01-04
RU2007117728A (ru) 2008-11-20
US20060121017A1 (en) 2006-06-08
HK1109068A1 (en) 2008-05-30
DE602005022471D1 (de) 2010-09-02
AU2005295754A1 (en) 2006-04-27
SI1809320T1 (sl) 2010-11-30
MX2007004534A (es) 2007-11-08
EP2198880B1 (en) 2016-11-23
AU2005295754B2 (en) 2010-09-09
CY1118597T1 (el) 2017-07-12
EP1809320A1 (en) 2007-07-25
HUE031245T2 (en) 2017-06-28
CA2584069A1 (en) 2006-04-27
RU2385736C2 (ru) 2010-04-10
LT2198880T (lt) 2017-02-27
KR20070074622A (ko) 2007-07-12
KR101333664B1 (ko) 2013-11-28
EP1809320B1 (en) 2010-07-21
CY1110838T1 (el) 2015-06-10
ES2614157T3 (es) 2017-05-29
CN101068565B (zh) 2010-11-17

Similar Documents

Publication Publication Date Title
SI1809320T1 (sl) Sestavki ki vsebujejo lipazo proteazo in amilazo za zdravljenje pankreasne insuficience
HUS2100051I1 (hu) Kompozíciók és eljárások sejtproliferációs rendellenességek kezelésére
WO2006024018A3 (en) Compositions for treating nociceptive pain
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
DE60330161D1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
WO2006068729A3 (en) Methods and compositions for enhancing iron absorption
MX2010007564A (es) Composiciones de limpieza y/o tratamiento.
TW200714283A (en) Method and composition for treating peripheral vascular diseases
IS2882B (is) Samsetning epóþílonhliðstæðna og virkra efna til efnameðferðar til þess að meðhöndla frumufjölgunarsjúkdóma
MX342128B (es) Compuestos farmaceuticos.
TW200740804A (en) Glucokinase activators
SG164368A1 (en) Treatment of cancer
WO2007092622A3 (en) Compositions and methods for treating bone
IL190796A0 (en) Compositions and their uses for gene therapy of bone conditions
MX2009012920A (es) Compuestos heptaciclicos y usos farmaceuticos de los mismos para la prevencion y tratamiento de diabetes y sindrome metabolico.
PL1779858T3 (pl) Zastosowanie związków selenu, w szczególności drożdży selenowych, do zmieniania funkcji poznawczych
ZA200705177B (en) Lyophilization of virosomes
MY177001A (en) Phenothiazine compounds for treating mild cognitive impairment
MY148921A (en) Enzymatic oil interesterification
TW200716088A (en) Formulations and methods for treating amyloidosis
WO2006069253A3 (en) Trefoil factors and methods of treating proliferation disorders using same
EP1879591B8 (en) Use of azapaullones for preventing and treating pancreatic autoimmune disorders
ATE519504T1 (de) Chromatin-remodellierende substanzen zur erhöhung der expression von pdx-1 und förderung der zelldifferenzierung
WO2004009029A3 (en) Compositions and methods for treating and preventing infection
WO2007005940A3 (en) Combinations of eszopiclone and didesmethylsibutramine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders